GLOBE registry to develop severity, quality-of-life, and cost tools for people with BMI over 25
Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.
This project will create tools to measure severity, quality of life, and the costs of living with a BMI over 25 using input from adults and clinicians.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medialis Ltd. Industry-sponsored |
| Locations | 1 site (Milton Keynes) |
| Trial ID | NCT07229027 on ClinicalTrials.gov |
What this trial studies
This observational registry will collect data from adults with a BMI over 25 and from healthcare professionals using online surveys and targeted qualitative feedback. It will capture symptoms, comorbidities, health-related quality of life, and direct and indirect costs across the full BMI spectrum while excluding participants on GLP-1 therapy. Clinician and patient perspectives will be integrated through mixed methods to develop disease-specific severity staging, a QoL instrument, and a comprehensive cost checklist. The resulting instruments aim to support earlier identification of needs and more inclusive outcome measurement.
Who should consider this trial
Good fit: Adults aged 18 or older with a self-reported BMI over 25 who can read and complete English-language surveys, are willing to participate, and are not receiving GLP-1 therapy.
Not a fit: People who cannot provide informed consent, have severe comorbidities that limit participation, cannot read English, or are currently on GLP-1 therapy are unlikely to benefit from or be eligible for this project.
Why it matters
Potential benefit: If successful, these tools could help clinicians and policymakers identify needs earlier, tailor care, and better capture the economic and quality-of-life burden for people with BMI over 25.
How similar studies have performed: While instruments and registries exist for obesity (BMI ≥30) and for patients receiving surgical or pharmacologic treatments, a comprehensive overweight-focused tool that integrates clinical, psychosocial, and cost data is largely novel and not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Patient group
1. Patient is aged ≥18 years at the time of survey completion.
2. Patient has a BMI over 25 (self-reported)
3. Patient is willing to participate in all study activities.
4. Patient is able to read, write, and converse in English.
* Healthcare professional participant must meet the following criteria for inclusion in the study:
1. HCP is aged ≥18 years at the time of survey completion.
2. HCP is suitably qualified and involved in the healthcare management of patients with a BMI over 25
3. HCP is willing to participate in all study activities.
4. HCP is able to read, write, and converse in English.
Exclusion Criteria:
A participant who meets any of the following criteria will be excluded from the study:
1. Participants do not have the cognitive capacity to provide informed consent.
2. Participants with severe co-morbidity that might affect study participation.
Where this trial is running
Milton Keynes
- Online recruitment — Milton Keynes, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Omolade Allen, PhD
- Email: omolade@medialis.co.uk
- Phone: +447502228066
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.